Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89


Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA.

Chu DS, Johnson SJ, Mallya UG, Davis MR, Sorg RA, Duh MS.

J Ophthalmic Inflamm Infect. 2013 Nov 6;3(1):64. doi: 10.1186/1869-5760-3-64.


Inpatient Utilization and Costs for Medicare Fee-for-Service Beneficiaries with Heart Failure.

Fitch K, Pelizzari PM, Pyenson B.

Am Health Drug Benefits. 2016 Apr;9(2):96-104.


Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.

Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Appl Health Econ Health Policy. 2011 Nov 1;9(6):377-87. doi: 10.2165/11592440-000000000-00000.


Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.

Klepser DG, Huether JR, Handke LJ, Williams CE.

J Manag Care Pharm. 2007 Nov-Dec;13(9):765-77.


Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.

Foster SA, Zhu B, Guo J, Nikai E, Ojeh C, Malatestinic W, Goldblum O, Kornberg LJ, Wu JJ.

J Manag Care Spec Pharm. 2016 Apr;22(4):396-405. doi: 10.18553/jmcp.2016.22.4.396.


Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.

Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.

J Manag Care Pharm. 2012 Nov-Dec;18(9):676-89.


Economic impact of tobramycin in patients with cystic fibrosis in a managed care population.

Wertz DA, Chang CL, Stephenson JJ, Zhang J, Kuhn RJ.

J Med Econ. 2011;14(6):759-68. doi: 10.3111/13696998.2011.621004. Epub 2011 Sep 27.


Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus.

Delea TE, Gokhale M, Makin C, Hussein MA, Vanderpoel J, Sandman T, Chang J, Sung J, Pinkston P, Gause D, Jackson M.

J Manag Care Pharm. 2007 May;13(4):349-59.


Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.

Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Appl Health Econ Health Policy. 2011 Sep 1;9(5):293-303. doi: 10.2165/11592430-000000000-00000.


Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.

Placzek H, Xu Y, Mu Y, Begelman SM, Fisher M.

J Manag Care Spec Pharm. 2015 Dec;21(12):1106-12.


Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.

Cohen R, Skup M, Ozbay AB, Rizzo J, Yang M, Diener M, Chao J.

J Med Econ. 2015 Jun;18(6):447-56. doi: 10.3111/13696998.2015.1021353. Epub 2015 Mar 27.


Pharmacy benefit spending on oral chemotherapy drugs.

Curtiss FR.

J Manag Care Pharm. 2006 Sep;12(7):570-7.


Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.

Curtis JR, Chastek B, Becker L, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier DH.

J Manag Care Spec Pharm. 2015 Apr;21(4):318-29.


Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.

Boccuzzi SJ, Martin J, Stephenson J, Kreilick C, Fernandes J, Beaulieu J, Hauch O, Kim J.

Curr Med Res Opin. 2009 Dec;25(12):2853-64. doi: 10.1185/03007990903196422.


An examination of periodontal treatment and per member per month (PMPM) medical costs in an insured population.

Albert DA, Sadowsky D, Papapanou P, Conicella ML, Ward A.

BMC Health Serv Res. 2006 Aug 16;6:103.


Healthcare utilization and costs of patients with rosacea in an insured population.

Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G.

J Drugs Dermatol. 2008 Jan;7(1):41-9.


Supplemental Content

Support Center